A novel and specific inhibitor of the AAA+ ATPase motor cytoplasmic dynein; perturbs protein trafficking within the primary cilium and affects other dynein-dependent processes, such as spindle pole focusing, kinetochore-microtubule attachment, melanosome aggregation and peroxisome motility in cultured cells.
FLI-06 is a novel potent and selective small molecule intercepting Notch signaling and the early secretory pathway (EC50 ~2.3 µM), identified by using automated microscopy to monitor the trafficking and processing of a ligand-independent Notch-GFP fusion reporter.
FPH1 is a potent and selective small molecule that induced Functional Proliferation of primary human Hepatocytes in vitro, identified by a high-throughput, cell-based screening using primary human hepatocytes.
Combination of Thiazovivin (ROCK inhibitor), SB431542 (TGFβ inhibitor), PD0325901 (MEK inhibitor), and CHIR99021 (GSK3 inhibitor) can enhance and accelerate reprogramming of human somatic cells (e.g., fibroblasts) into iPSCs.
Combination of LSB and three other inhibitors/3i (i.e., CHIR99021/GSK3 inhibitor, SU5402/FGF-VEGF-PDGF inhibitor, DAPT/Notch inhibitor) can induce very rapid and efficient neuronal differentiation of human ESC and iPSC into nociceptors.
An unique PPARγ modulator that has potent anti-diabetic activity through blocking the Cdk5-mediated phosphorylation of PPARγ, but completely lacks classical transcriptional agonism that accounts for other PPARγ agonists’ side effects.